Scientists in the US have developed a drug used in cancer treatment to awaken the so-called sleeper cells in patients receiving treatment for HIV, the virus that causes AIDS. Researchers said they had found a way to stimulate the emergence of the virus using an anti-cancer drug, noting that this may be the first step towards the development of a potential cure for the virus that causes AIDS. Under the supervision of David Margolis of The University of North Carolina at Chapel Hill, researchers were able to cooperate with their colleagues from other universities and researchers at global pharmaceutical and chemical company Merck, proving that this molecular mechanism works using a specific drug. Known in the US as a medicine against cancer, it is traded under the brand name Zolinza. "We believe that the disruption and clearance of these virus reservoirs is a critical first step to the daunting challenge of finding a cure for HIV/AIDS," said Merck Research Laboratories Vice President Daria Hazuda. This is the first published study to show the potential for inhibitors to attack latency within dormant virus pools in a translational clinical study.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor